Mario Maufus1, Marie Antoinette Sevestre-Pietri2,3, Carmine Sessa4, Bernard Pignon5, Harald Egelhofer6,7, Stephane Dupas2, Philippe Nguyen8, Celine Genty9, Gilles Pernod1,3. 1. 1 Department of Vascular Medicine, University Hospital Grenoble-Alpes, France. 2. 2 Department of Vascular Medicine, University Hospital Amiens, France. 3. 3 Université Grenoble Alpes - CNRS, TIMC-IMAG UMR 5525/Themas, Grenoble, France. 4. 4 Department of Vascular Surgery, University Hospital Grenoble-Alpes, France. 5. 5 Cell Therapy Unit, University Hospital Reims, France. 6. 6 Cell Therapy Unit, University Hospital Grenoble-Alpes, France. 7. 7 Etablissement Français du Sang, Rhône-Alpes Grenoble, France. 8. 8 Hematology Laboratory, University Hospital Reims, France. 9. 9 Centre of Clinical Research, University Hospital Grenoble-Alpes, France.
Abstract
BACKGROUND: Cell therapy is an emerging potential biotherapy for critical limb ischaemia (CLI) patients who are not eligible for revascularization. However, the findings on this technique's efficacy are inconsistent. Trials investigating this topic focused on the more severe CLI patients who were often beyond any therapy. Therefore, identifying those who may truly benefit from cell transplantation is now warranted. To this end, we studied the prognostic value of tcPO2 for major amputation after 1 year in patients treated with bone marrow-derived cells. PATIENTS AND METHODS: CLI patients ineligible for revascularization were included in a cell-therapy pilot study. On inclusion, patients underwent tcPO2 measurement in supine and sitting positions. For a tcPO2 < 10 mmHg in the supine position, the vascular reserve was defined by tcPO2 > 30 mmHg in the sitting position. Patients were administered intramuscular injections of mononuclear cells derived from aspirated bone marrow. RESULTS: In total, 25 patients (a lower limbs) were included for analysis. At inclusion, 11 lower limbs had tcPO2 at rest > 10 mmHg, and 16 lower limbs had a tcPO2 < 10 mmHg. The success probability for cell therapy was 0.79 (95 % CI 0.38-0.94) and 0.44 (95 % CI 0.18-0.67), respectively (p = 0.1). Of the 16 limbs with tcPO2 < 10 mmHg, the success rate was considerably higher in patients demonstrating a tcPO2 increase in a sitting position of over 30 mmHg (6/8, success probability 0.71, 95 % CI 0.26-0.92) compared to those without (2/8, success probability 0.15, 95 % CI 0.01-0.48, p = 0.03). CONCLUSIONS: For patients with chronic CLI for whom cellular therapy is a therapeutic option, a tcPO2 < 10 mmHg at rest, without vascular reserve (i. e. < 30 mmHg when sitting), is a prognostic indicator for poor outcome. .
BACKGROUND: Cell therapy is an emerging potential biotherapy for critical limb ischaemia (CLI) patients who are not eligible for revascularization. However, the findings on this technique's efficacy are inconsistent. Trials investigating this topic focused on the more severe CLI patients who were often beyond any therapy. Therefore, identifying those who may truly benefit from cell transplantation is now warranted. To this end, we studied the prognostic value of tcPO2 for major amputation after 1 year in patients treated with bone marrow-derived cells. PATIENTS AND METHODS: CLI patients ineligible for revascularization were included in a cell-therapy pilot study. On inclusion, patients underwent tcPO2 measurement in supine and sitting positions. For a tcPO2 < 10 mmHg in the supine position, the vascular reserve was defined by tcPO2 > 30 mmHg in the sitting position. Patients were administered intramuscular injections of mononuclear cells derived from aspirated bone marrow. RESULTS: In total, 25 patients (a lower limbs) were included for analysis. At inclusion, 11 lower limbs had tcPO2 at rest > 10 mmHg, and 16 lower limbs had a tcPO2 < 10 mmHg. The success probability for cell therapy was 0.79 (95 % CI 0.38-0.94) and 0.44 (95 % CI 0.18-0.67), respectively (p = 0.1). Of the 16 limbs with tcPO2 < 10 mmHg, the success rate was considerably higher in patients demonstrating a tcPO2 increase in a sitting position of over 30 mmHg (6/8, success probability 0.71, 95 % CI 0.26-0.92) compared to those without (2/8, success probability 0.15, 95 % CI 0.01-0.48, p = 0.03). CONCLUSIONS: For patients with chronic CLI for whom cellular therapy is a therapeutic option, a tcPO2 < 10 mmHg at rest, without vascular reserve (i. e. < 30 mmHg when sitting), is a prognostic indicator for poor outcome. .
Authors: Andrea L DiCarlo; Radia Tamarat; Carmen I Rios; Marc Benderitter; Christine W Czarniecki; Theresa C Allio; Francesca Macchiarini; Bert W Maidment; Jean-Rene Jourdain Journal: Radiat Res Date: 2017-06-12 Impact factor: 2.841
Authors: J Husakova; R Bem; V Fejfarova; A Jirkovska; V Woskova; R Jarosikova; V Lovasova; E B Jude; M Dubsky Journal: J Diabetes Res Date: 2022-04-11 Impact factor: 4.061